Source:http://linkedlifedata.com/resource/pubmed/id/15122749
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2004-5-3
|
pubmed:abstractText |
Acute hepatitis C often progresses to chronic infection. We undertook a randomized controlled trial to determine whether short-term therapy with interferon (IFN) during acute hepatitis C is effective in preventing the development of chronic hepatitis. Thirty patients with acute hepatitis C were randomized into 1 of 2 treatment groups. IFN therapy was initiated 8 weeks after the onset of acute hepatitis in the early-intervention group and after 1 year of observation in the late-intervention group. Short-term therapy consisted of natural IFN-alfa (6 million units) administered on consecutive days for a period of 4 weeks. Any signs of recrudescence of disease were immediately followed by interval IFN therapy (3 times weekly for 20 weeks). In the early-intervention group, short-term therapy was associated with a sustained virological response in 13 of 15 patients (87%). Follow-up treatment was associated with a sustained virological response in both of the remaining 2 patients (100%). The sustained virological response rate was significantly higher in the early-intervention group (87%, 13 of 15 patients after short-term therapy alone, and 100%, 15 of 15 patients after short-term with or without follow-up therapy) than in the late-intervention group (40%, 6 of 15 patients after short-term therapy alone, and 53%, 8 of 15 patients after short-term therapy with or without follow-up therapy, P =.021 and P =.006, respectively). In conclusion, short-term (4 weeks) IFN treatment of patients with acute hepatitis C may be associated with satisfactory results, if initiated at an early stage of the disease.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0270-9139
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1213-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:15122749-Acute Disease,
pubmed-meshheading:15122749-Adult,
pubmed-meshheading:15122749-Antiviral Agents,
pubmed-meshheading:15122749-Female,
pubmed-meshheading:15122749-Hepacivirus,
pubmed-meshheading:15122749-Hepatitis C,
pubmed-meshheading:15122749-Hepatitis C, Chronic,
pubmed-meshheading:15122749-Humans,
pubmed-meshheading:15122749-Interferon-alpha,
pubmed-meshheading:15122749-Male,
pubmed-meshheading:15122749-Middle Aged,
pubmed-meshheading:15122749-RNA, Viral,
pubmed-meshheading:15122749-Time Factors,
pubmed-meshheading:15122749-Treatment Outcome
|
pubmed:year |
2004
|
pubmed:articleTitle |
Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial.
|
pubmed:affiliation |
Department of Internal Medicine, Shin-Kokura Hospital, Fukuoka, Japan. h-nomura@shin-kokura.gr.jp
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|